论文部分内容阅读
目的:研究抗病毒治疗对原发性肝癌的慢性乙型肝炎相关危险因素的干预作用。方法:回顾性分析青岛市传染病医院2010年2月至2012年6月住院的原发性肝癌患者病例249例,经统一编制的调查表记录相关数据,分析比较抗病毒治疗组与无抗病毒治疗组两组间各因素的分布差异。结果:抗病毒治疗组与无抗病毒治疗组患者被诊断为HCC前的HBV感染时间、肝硬化史以及HBV DNA载量,P<0.05,差异均有统计学意义;两组间的HBV感染模式、AFP、CEA差异无统计学意义;相关肝功能指标经统计学处理差异均有意义。结论:抗病毒治疗可以明显降低慢乙肝相关致癌因素在患者中的分布,有效抑制HBV DNA复制,进而或可降低乙肝相关性肝癌的发病率。
Objective: To study the intervention effect of antiviral therapy on the risk factors of chronic hepatitis B in primary liver cancer. Methods: A retrospective analysis of Qingdao Infectious Disease Hospital from February 2010 to June 2012 hospitalized patients with primary liver cancer in 249 cases, the data compiled by the unified questionnaire, analysis and comparison of anti-virus treatment group with no anti-virus The difference between the two groups in the treatment group. Results: The time of HBV infection, the history of liver cirrhosis and the HBV DNA load before HCC were diagnosed in the antiviral therapy group and those in the non-antiviral treatment group, P <0.05, the differences were statistically significant. The HBV infection pattern , AFP, CEA no significant difference; related indicators of liver function by statistical differences were significant. Conclusion: Antiviral therapy can significantly reduce the distribution of chronic hepatitis B-related oncogenic factors in patients and effectively inhibit HBV DNA replication, which in turn can reduce the incidence of hepatitis B-related liver cancer.